v3.26.1
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Disaggregation Of Revenue [Line Items]          
Sources of revenue, description     We derive our revenue from two sources: (i) Diagnostic Tests, providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Development Services, providing diagnostic testing services to biopharmaceutical, life sciences, and diagnostic companies.    
Revenue recognized     $ 1,000    
Deferred revenue $ 205   $ 205   $ 961
Revenue | Minimum | Customer Concentration Risk | Medicare          
Disaggregation Of Revenue [Line Items]          
Concentration risk, percentage 35.00% 33.00% 34.00% 35.00%  
Up Front Cash Payments          
Disaggregation Of Revenue [Line Items]          
Deferred revenue $ 200   $ 200    
Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesNoncurrent          
Disaggregation Of Revenue [Line Items]          
Non-current deferred revenue $ 100   $ 100   $ 100